메뉴 건너뛰기
Journal of Clinical Oncology
Volumn 23, Issue 32, 2005, Pages 8161-8164
Phase III prostate cancer prevention trials: Are the costs justified?
Author keywords

[No Author keywords available]
Indexed keywords

ALPHA TOCOPHEROL; DUTASTERIDE; FINASTERIDE; PLACEBO; SELENIUM;
EID: 33644679967     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2005.02.7987     Document Type: Review
Times cited : (18)
References (13)
  • 1
    • 0037812658 scopus 로고    scopus 로고
    • The influence of finasteride on the development of prostate cancer
    • Thompson IM, Goodman PJ, Tangen CM, et al: The influence of finasteride on the development of prostate cancer. N Engl J Med 349:215-224, 2003
    • (2003) N Engl J Med , vol.349 , pp. 215-224
    • Thompson, I.M.1    Goodman, P.J.2    Tangen, C.M.3
  • 2
    • 13744264090 scopus 로고    scopus 로고
    • Designing the Selenium and Vitamin E Cancer Prevention Trial (SELECT)
    • Lippman SM, Goodman PJ, Klein EA, et al: Designing the Selenium and Vitamin E Cancer Prevention Trial (SELECT). J Natl Cancer Inst 97:94-102, 2005
    • (2005) J Natl Cancer Inst , vol.97 , pp. 94-102
    • Lippman, S.M.1    Goodman, P.J.2    Klein, E.A.3
  • 3
    • 4544248276 scopus 로고    scopus 로고
    • REDUCE Study Group: Chemoprevention of prostate cancer in men at high risk: Rationale and design of the reduction by dutasteride of prostate cancer events (REDUCE) trial
    • Andriole G, Bostwick D, Brawley O, et al; REDUCE Study Group: Chemoprevention of prostate cancer in men at high risk: Rationale and design of the reduction by dutasteride of prostate cancer events (REDUCE) trial. J Urol 172:1314-1317, 2004
    • (2004) J Urol , vol.172 , pp. 1314-1317
    • Andriole, G.1    Bostwick, D.2    Brawley, O.3
  • 4
    • 10344251615 scopus 로고    scopus 로고
    • Does finasteride alter the pathology of the prostate and cancer grading?
    • Bostwick DG, Qian J, Civantos F, et al: Does finasteride alter the pathology of the prostate and cancer grading? Clin Prostate Cancer 2:228-235, 2004
    • (2004) Clin Prostate Cancer , vol.2 , pp. 228-235
    • Bostwick, D.G.1    Qian, J.2    Civantos, F.3
  • 5
    • 14644391613 scopus 로고    scopus 로고
    • Gleason grade remains an important prognostic predictor in men diagnosed with prostate cancer while on finasteride therapy
    • Carver BS, Kattan MW, Scardino PT, et al: Gleason grade remains an important prognostic predictor in men diagnosed with prostate cancer while on finasteride therapy. BJU Int 95:509-512, 2005
    • (2005) BJU Int , vol.95 , pp. 509-512
    • Carver, B.S.1    Kattan, M.W.2    Scardino, P.T.3
  • 6
    • 0346905442 scopus 로고    scopus 로고
    • Prevention of prostate cancer with finasteride: US/European perspective
    • Thompson IM, Klein EA, Lippman SM, et al: Prevention of prostate cancer with finasteride: US/European perspective. Eur Urol 44:650-655, 2003
    • (2003) Eur Urol , vol.44 , pp. 650-655
    • Thompson, I.M.1    Klein, E.A.2    Lippman, S.M.3
  • 7
    • 1542321126 scopus 로고    scopus 로고
    • Implementation of the Prostate Cancer Prevention Trial
    • Goodman PJ, Tangen CM, Crowley JJ, et al: Implementation of the Prostate Cancer Prevention Trial. Control Clin Trials 25:203-222, 2004
    • (2004) Control Clin Trials , vol.25 , pp. 203-222
    • Goodman, P.J.1    Tangen, C.M.2    Crowley, J.J.3
  • 8
    • 0345868342 scopus 로고    scopus 로고
    • Statistical design issues and other practical considerations for conducting phase III prostate cancer prevention trials
    • Tangen CM, Goodman PJ, Crowley JJ, et al: Statistical design issues and other practical considerations for conducting phase III prostate cancer prevention trials. J Urol 171:S64-S67, 2004
    • (2004) J Urol , vol.171
    • Tangen, C.M.1    Goodman, P.J.2    Crowley, J.J.3
  • 9
    • 15744371131 scopus 로고    scopus 로고
    • Implications of the prostate cancer prevention trial: A decision analysis model of survival outcomes
    • Lotan Y, Cadeddu JA, Lee JJ, et al: Implications of the prostate cancer prevention trial: A decision analysis model of survival outcomes. J Clin Oncol 23:1911-1920, 2005
    • (2005) J Clin Oncol , vol.23 , pp. 1911-1920
    • Lotan, Y.1    Cadeddu, J.A.2    Lee, J.J.3
  • 10
    • 2442715038 scopus 로고    scopus 로고
    • Prevalence of prostate cancer among men with a prostate-specific antigen level < or = 4.0 ng per milliliter
    • Thompson IM, Pauler DK, Goodman PJ, et al: Prevalence of prostate cancer among men with a prostate-specific antigen level < or = 4.0 ng per milliliter. N Engl J Med 350:2239-2246, 2004
    • (2004) N Engl J Med , vol.350 , pp. 2239-2246
    • Thompson, I.M.1    Pauler, D.K.2    Goodman, P.J.3
  • 11
    • 0034015673 scopus 로고    scopus 로고
    • Profile of men randomized to the prostate cancer prevention trial: Baseline health-related quality of life, urinary and sexual functioning, and health behaviors
    • Moinpour CM, Lovato LC, Thompson IM, Jr., et al: Profile of men randomized to the prostate cancer prevention trial: Baseline health-related quality of life, urinary and sexual functioning, and health behaviors. J Clin Oncol 18:1942-1953, 2000
    • (2000) J Clin Oncol , vol.18 , pp. 1942-1953
    • Moinpour, C.M.1    Lovato, L.C.2    Thompson Jr., I.M.3
  • 12
    • 7444266768 scopus 로고    scopus 로고
    • High-grade prostatic intraepithelial neoplasia
    • Bostwick DG, Qian J: High-grade prostatic intraepithelial neoplasia. Mod Pathol 17:360-379, 2004
    • (2004) Mod Pathol , vol.17 , pp. 360-379
    • Bostwick, D.G.1    Qian, J.2

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.